Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Chiang, Kun Chun ^a,b   Yeh, Chun Nan ^a,c   Ueng, Shir Hwa ^a   Hsu, Jun Te ^a   Yeh, Ta Sen ^a   Jan, Yi Yin ^a   Hwang, Tsann Long ^a   Chen, Miin Fu ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c Department of Surgery ^*  (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMYLASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; GEMCITABINE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL RADIOGRAPHY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE REGIMEN; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NUTRITIONAL STATUS; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DECISION SUPPORT TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860530929     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-77     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. American Cancer Society Cancer Facts & Figures 2008 2008, Atlanta: American Cancer Society, http://www.cancer.org/acs/groups/content/@nho/documents/document/2008cafffinalsecuredpdf.pdf, American Cancer Society.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66. 10.3322/canjclin.57.1.43, 17237035.
4. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990, 211:447-458. 10.1097/00000658-199004000-00011, 1358031, 2322039.
5. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997, 226:248-260. 10.1097/00000658-199709000-00004, 1191017, 9339931.
6. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann Surg 1995, 221:59-66. 10.1097/00000658-199501000-00007, 1234495, 7826162.
7. Haller DG. New perspectives in the management of pancreas cancer. Semin Oncol 2003, 30:3-10.
8. Ellsmere J, Mortele K, Sahani D, Maher M, Cantisani V, Wells W, Brooks D, Rattner D. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma?. Surg Endosc 2005, 19:369-373. 10.1007/s00464-004-8712-5, 15624058.
9. Gulliver DJ, Baker ME, Cheng CA, Meyers WC, Pappas TN. Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. AJR Am J Roentgenol 1992, 159:503-507.
10. Prokesch RW, Chow LC, Beaulieu CF, Bammer R, Jeffrey RB. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 2002, 224:764-768. 10.1148/radiol.2243011284, 12202711.
11. Saldinger PF, Reilly M, Reynolds K, Raptopoulos V, Chuttani R, Steer ML, Matthews JB. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms?. J Gastrointest Surg 2000, 4:233-237. 10.1016/S1091-255X(00)80071-2, 10769085.
12. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997, 15:928-937.
13. Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2008, 15:429-435. 10.1007/s00534-007-1240-7, 18670846.
14. Clarke DL, Thomson SR, Madiba TE, Sanyika C. Preoperative imaging of pancreatic cancer: a management-oriented approach. J Am Coll Surg 2003, 196:119-129. 10.1016/S1072-7515(02)01609-5, 12517564.
15. Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008, 14:3750-3753. 10.3748/wjg.14.3750, 2719240, 18595144.
16. Ho JM, Eysselein VE, Stabile BE. The value of endoscopic ultrasonography in predicting resectability and margins of resection for periampullary tumors. Am Surg 2008, 74:1026-1029.
17. Maithel SK, Maloney S, Winston C, Gonen M, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008, 15:3512-3520. 10.1245/s10434-008-0134-5, 18781364.
18. Klauss M, Mohr A, von Tengg-Kobligk H, Friess H, Singer R, Seidensticker P, Kauczor HU, Richter GM, Kauffmann GW, Grenacher L. A new invasion score for determining the resectability of pancreatic carcinomas with contrast-enhanced multidetector computed tomography. Pancreatology 2008, 8:204-210. 10.1159/000128557, 18434758.
19. Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 2005, 8:377-384. 10.1007/s11938-005-0040-x, 16162303.
20. Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ 2004, 329:668-673. 10.1136/bmj.329.7467.668, 517650, 15374918.
21. Misek DE, Patwa TH, Lubman DM, Simeone DM. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 2007, 5:1034-1041.
22. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004, 11:4-10. 10.1007/s00534-002-0775-x, 15747028.
23. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol 2008, 23:23-33. 10.1111/j.1440-1746.2007.04868.x, 18171340.
24. Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998, 206:373-378.
25. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, Coste J, Louvel A, Roseau G, Couturier D, Bonnin A. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. AJR Am J Roentgenol 1998, 170:1315-1322.
26. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997, 168:1439-1443.
27. Steinberg WM, Barkin J, Bradley EL, Di Magno E, Layer P. Workup of a patient with a mass in the head of the pancreas. Pancreas 1998, 17:24-30. 10.1097/00006676-199807000-00002, 9667516.
28. Conlon KC, Dougherty E, Klimstra DS, Coit DG, Turnbull AD, Brennan MF. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996, 223:134-140. 10.1097/00000658-199602000-00004, 1235088, 8597506.
29. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999, 229:729-738. 10.1097/00000658-199905000-00016, 1420818, 10235532.
30. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, Schwaiger M, Roder JD, Siewert JR. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000, 24:1121-1129. 10.1007/s002680010182, 11036292.
31. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999, 40:1784-1791.
32. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, Konishi J. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999, 54:248-252. 10.1016/S0009-9260(99)91160-1, 10210345.
33. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979, 5:957-971. 10.1007/BF01542654, 94699.
34. Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers] [in Chinese]. Zhonghua Nei Ke Za Zhi 2005, 44:741-744.
35. Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology 1998, 45:867-872.
36. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007, 6:641-645.
37. Kiliç M, Göçmen E, Tez M, Ertan T, Keskek M, Koç M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006, 49:241-244. 3207573, 16948881.
38. Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006, 32:271-275. 10.1097/01.mpa.0000202953.87740.93, 16628082.
39. Moon HJ, An JY, Heo JS, Choi SH, Joh JW, Kim YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 2006, 32:37-43. 10.1097/01.mpa.0000194609.24606.4b, 16340742.
40. Shimada K, Sakamoto Y, Sano T, Kosuge T. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006, 139:288-295. 10.1016/j.surg.2005.08.004, 16546491.
41. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, Baumgardner JA, Cummings OW, Jacobson LE, Broadie TA, Canal DF, Goulet RJ, Curie EA, Cardenes H, Watkins JM, Loehrer PJ, Lillemoe KD, Madura JA. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004, 139:718-727. 10.1001/archsurg.139.7.718, 15249403.
42. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005, 31:164-169. 10.1016/j.ejso.2004.09.007, 15698733.
43. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006, 24:2897-2902. 10.1200/JCO.2005.05.3934, 16782929.
44. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004, 11:644-649. 10.1245/ASO.2004.11.025, 15197014.
45. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 1993, 72:3091-3098. 10.1002/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V, 8221576.
46. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001, 39:210-213. 10.1207/S15327914nc392_8, 11759282.
47. Ruiz-Tovar J, Martín-Pérez E, Fernández-Contreras ME, Reguero-Callejas ME, Gamallo-Amat C. Impact of preoperative levels of hemoglobin and albumin on the survival of pancreatic carcinoma [English and Spanish]. Rev Esp Enferm Dig 2010, 102:631-636.
48. von Meyenfeldt M. Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs 2005, 9(Suppl 2):S35-S38.
49. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer 1999, 35:106-110. 10.1207/S15327914NC352_2, 10693162.